Efficacy of venetoclax based salvage chemotherapy followed by “Minimal Residual Disease driven”-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia

Elisabetta TodiscoOnco-hematology Division, IEO, European Institute of Oncology IRCCS, Milano, Italy; Correspondence[email protected]

Federica GigliOnco-hematology Division, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Simona SammassimoOnco-hematology Division, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Chiara CamisaschiLaboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Patrizia MancusoLaboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Chiara RonchiniLaboratory of Clinical Genomics, IEO, European Institute of Oncology IRCCS, Milano, Italy;

http://orcid.org/0000-0003-3908-4021

Safaa RamadanOnco-hematology Division, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Francesco BertoliniLaboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Rocco PastanoOnco-hematology Division, IEO, European Institute of Oncology IRCCS, Milano, Italy;

Corrado TarellaOnco-hematology Division, IEO, European Institute of Oncology IRCCS, Milano, Italy; ;Department of Health Sciences, University of Milan, Milano, Italy

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy of venetoclax based salvage chemotherapy followed by “Minimal Residual Disease driven”-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia

Information for

Open access

Opportunities

Help and information

Efficacy of venetoclax based salvage chemotherapy followed by “Minimal Residual Disease driven”-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature